Score Your Stock

US stock · figures in US dollars · scored on full-year results

Incyte Incyte Corporation

INCY · Healthcare · Biotechnology
Top 47% of scored stocks
OkayTop 47% of scored stocks
Weak SpotLimited Data

Incyte scores 55/100 on fundamentals: in the top 47% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.

Best
Financial 100
Weakest
Price 0
  • Carries a Weak Spot flag
  • Carries a Limited Data flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 24.4b#366 of 503 in the S&P 500EPSUS$ 7.85P/E60.9×✗ vs sector median 29.6×P/B4.4×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 9% in the S&P 50052w range · 72% of range89.25132.60
as of 31 Oct 2026

Nearby peers

Ranks #27 of 60 in Healthcare by score

#1Universal Health Services79#25DaVita56#26Bristol Myers Squibb55
#27Incyte55
#28Bio-Techne55#29HCA Healthcare54

One-Minute Summary

Why Incyte scores 55

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

38
Why 38?
Pillar score: (0 + 2 + 0 + 1) = 3 of 8 points → 38 · 1 N/A skipped
Return on Equity (ROE)7%Weak4-Year Revenue Growth+18%/yrStrong4-Year Profit Growth-12%/yrWeakNet Profit Margin7%Okay

No data: Quarterly Momentum

Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -32.5%Equity ↑ +8.7%ROE % 7.1%
Net ProfitEquityROE %
598m33m1.3b403m5.2b3.4b5.2b5.6b202320242025TTM11.5%0.9%24.9%7.1%

Revenue & Net Profit, with Net Margin

Revenue ↑ +62.6%Net Profit ↓ -32.5%Net Margin % 6.7%
RevenueNet ProfitNet Margin %
3.7b4.2b5.1b6.0b598m33m1.3b403m202320242025TTM16.2%0.8%25%6.7%

Sales grew about 62.6% over 4 years: customers keep spending more with this company.

Profit fell about 32.5% from where it was 4 years ago: the boom has cooled off.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +37.7%Net Profit ↑ +44.6%Net Margin % 35%
RevenueNet ProfitNet Margin %
1.2b1.4b1.5b1.3b1.7b405m424m299m303m586mQ2'25Q3'25Q4'25Q1'26Q2'2633.3%31.1%19.9%23.8%35%
▲

Sales grew about 37.7% over the last 5 quarters: customers keep spending more with this company.

Profit grew about 44.6% over the last 5 quarters: the business is keeping more of what it earns.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0×StrongCurrent Ratio3.8×StrongInterest Coverage341.6×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt → -2.3%Equity ↑ +8.7%D/E 0×
Total DebtEquityD/E
38m44m40m37m5.2b3.4b5.2b5.6b202320242025TTM0×0×0×0×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +18.9%Current Liabilities ↑ +15.9%Current Ratio 3.8×
Current AssetsCurrent LiabilitiesCurrent Ratio
4.6b3.2b5.0b5.5b1.2b1.6b1.5b1.4b202320242025TTM3.7×2×3.3×3.8×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +50.1%Free CF ↑ +51.4%
Operating CFFree CF
497m335m1.4b745m449m235m1.3b680m202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash → +1.9%Short-Term Debt ↑ +7.7%Total Debt → -2.3%
CashShort-Term DebtTotal Debt
3.2b1.7b3.1b3.3b9m10m10m10m38m44m40m37m202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio60.9×WeakP/B Ratio4.4×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 127.81US$ 109.06US$ 90.30Oct '25Feb '26Jun '26Oct '26

The share price is up about 28.8% over the past year.

Why 60?
Pillar score: (1 + 1 + 2 + 0 + 2) = 6 of 10 points → 60 · 1 N/A skipped
Earnings ConsistencyUnevenOkayDebt Trend (4yr)StableOkayShare Count Trend (4yr)-3%/yrStrongInventory vs Sales (4yr)+11.1 pp/yr vs salesWeakAsset Turnover Trend (4yr)+51.4%Strong

No data: Quarterly Consistency

Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +62.6%Inventory ↑ +113.2%Inv. % of Rev. 2.2%
RevenueInventoryInv. % of Rev.
3.7b4.2b5.1b6.0b63m59m101m134m202320242025TTM1.7%1.4%2%2.2%
Ranks #27 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#25DaVita56#26Bristol Myers Squibb55
#27Incyte (you)55
#28Bio-Techne55#29HCA Healthcare54

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 6.0bUS$ 403.4mUS$ 745.0mUS$ 679.9mUS$ -65.1mUS$ 3.3bUS$ 37.4mUS$ 9.8mUS$ 5.6bUS$ 5.5bUS$ 1.4bUS$ 7.3bUS$ 1.6bUS$ 134.3m-7%7%0.0×3.8×341.6×----
2025US$ 5.1bUS$ 1.3bUS$ 1.4bUS$ 1.3bUS$ -83.9mUS$ 3.1bUS$ 40.4mUS$ 10.2mUS$ 5.2bUS$ 5.0bUS$ 1.5bUS$ 7.0bUS$ 1.8bUS$ 101.1mUS$ 0.0m25%25%0.0×3.3×686.5×0%15.6×3.9×0.3
2024US$ 4.2bUS$ 32.6mUS$ 335.3mUS$ 235.2mUS$ -100.2mUS$ 1.7bUS$ 43.5mUS$ 10.0mUS$ 3.4bUS$ 3.2bUS$ 1.6bUS$ 5.4bUS$ 2.0bUS$ 58.9mUS$ 0.0m1%1%0.0×2.0×139.9×0%413.0×3.9×-
2023US$ 3.7bUS$ 597.6mUS$ 496.5mUS$ 449.0mUS$ -47.5mUS$ 3.2bUS$ 38.3mUS$ 9.1mUS$ 5.2bUS$ 4.6bUS$ 1.2bUS$ 6.8bUS$ 1.6bUS$ 63.0mUS$ 0.0m12%16%0.0×3.8×328.0×0%23.6×2.7×0.3